Diabetes drug shows promise for gout in new trial
NCT ID NCT06674109
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 40 times
Summary
This study tests whether empagliflozin, a drug used for diabetes, can lower uric acid levels and reduce inflammation in people with gout. Sixty adults with gout and high urate levels will receive either empagliflozin or a placebo for 12 weeks. The goal is to see if this drug can help control gout and prevent flares.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT AND HYPERURICEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.